$CELG Recent News A teachable moment: Here are my worst

New Post Public Reply Private Reply Replies (0) Message Board

Dec 23, 2014 at 1:05 PM

$CELG Recent News

A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Today - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt

Dow Tops 18000 48 min ago - The Wall Street Journal Interactive Edition
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger? 11:21 a.m. Today - Seeking Alpha
Celgene (CELG) Weak On High Volume Today 10:02 a.m. Today - TheStreet.com
RBC’s 5 Top Biotech Stocks to Buy for 2015 9:07 a.m. Today - 247WallSt.com
5 Healthcare Stocks to Buy 4:04 a.m. Today - InvestorPlace.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More 1:37 p.m. Dec. 22, 2014 - TheStreet.com
Trade of the Day: IBB Up 40% YTD – Buy, Sell or Hold? 7:17 p.m. Dec. 21, 2014 - InvestorPlace.com
Juno Therapeutics IPO Hot As Cancer Curers In Demand 5:32 p.m. Dec. 19, 2014 - Investors Business Daily
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half 10:46 a.m. Dec. 19, 2014 - TheStreet.com
Europe advisory committee supports expanded label for Revlimid 9:16 a.m. Dec. 19, 2014 - Seeking Alpha
European Panel Gives Positive Opinion on Celgene Cancer Drug 8:59 a.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
Celgene (CELG) Leads The Pack In Pre-Market Activity 8:37 a.m. Dec. 19, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally 8:10 p.m. Dec. 18, 2014 - TheStreet.com
'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield 6:00 a.m. Dec. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity 8:16 p.m. Dec. 17, 2014 - TheStreet.com
Trade of the Day: More Gains to Come in Top-Ranked CELG Stock 7:20 p.m. Dec. 17, 2014 - InvestorPlace.com

Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Activewear Faces Major Class Action Lawsuit

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Sintilimab Poised for New Milestone in Melanoma Fight

An Opening Shot: NMPA's Decision Window Well, here's the latest chapter in the saga of battling advanced melanoma with some real gritty numbers behind it. Innovent Biologics has thrown its hat back in the ring with news that the China National Medical Products Administration (NMPA) has embraced a new indication application for their drug sintilimab. They're teaming it up...

ROKAE Hits 10,000 Delivery Mark for Robotic Arms

ROKAE's Big 10K: A Milestone Worth Noting Alright, if you've been around the block as long as I have, you know the robotics game isn't just about making cool gadgets—it's about hitting those serious deployment numbers. ROKAE Robotics just rolled its 10,000th humanoid force-controlled arm off the line in Shandong, and this ain't just another notch on their belt. This...

Metallium's U.S. Supply Chain Ambitions Hinge on Traxys MOU

Metallium and Traxys Partner to Boost U.S. Critical Metals Out there in Houston, October's cooked up a potential game-changer for U.S. critical metals supply like no one's business. Metallium Limited—those savvy cats juggling ASX and OTC markets—just laid down a non-binding Memorandum of Understanding (MOU) with Traxys North America LLC. The goal? To sharpen up and...

Bank of America Faces Legal Battle Over Compliance Failures

Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...

Duke Energy's Battle Against Energy Vampires Heats Up

Unplugging Hidden Electricity Drains Ever wonder why your electric bill has been sneakily creeping up? You might think it's just the AC running full blast or lights left on, but surprise, surprise—there’s a whole army of “energy vampires” quietly sucking the juice out of your home. Duke Energy Florida is drawing attention to this sneaky leak, especially around...

WuXi AppTec Boosts Guidance Amid Strong CRDMO Growth

Unpacking WuXi AppTec's Latest Performance Boost WuXi AppTec, the pharmaceutical giant, isn't just coasting on its past successes. The way they're riding the contract research, development, and manufacturing (CRDMO) train straight through Q1 to Q3 of 2026 shows they're not just here for show. They've hiked up the stakes with strong metrics across the board, warranting a...

University of Phoenix Grads Gain High Praise from Managers

Forget the stereotypes that tag University of Phoenix as just another factory for diplomas. The latest survey results paint a picture of graduates who seem to be real go-getters in the workplace. We’ve got managers from all over singing the praises of these alums, with a whopping 96% ready to vouch for them stepping into bigger roles. Not just talk, folks, this is their...

Shenzhen Hosts FDI Moot: A Key Milestone for Arbitration

Shenzhen Steps into the Arbitration Spotlight In a move that's bound to tweak some eyebrows in the legal realm, Shenzhen just hosted the 2026 Foreign Direct Investment International Arbitration Moot (FDI Moot) Global Finals. This marks the first time the finals have landed on Chinese soil, and folks, that's a big deal. It’s a hefty nod to China's expanding credibility...

Kevin Burke Strengthens Latham's Private Equity Team

Big Moves in the Legal Arena Holy guacamole, folks—Kevin Burke just landed a plum spot at Latham & Watkins, stepping into their Mergers & Acquisitions and Private Equity team in New York. You might ask, who cares? Well, savvy investors and PE players should pay attention because moving legal minds like Burke can stir up the whole private equity scene. Who's This Burke...